Cite
Ozkaya A, Alkin Z, Ozkaya HM, et al. Is spectral-domain optical coherence tomography essential for flexible treatment regimens with ranibizumab for neovascular age-related macular degeneration?. J Ophthalmol. 2013;2013:786107doi: 10.1155/2013/786107.
Ozkaya, A., Alkin, Z., Ozkaya, H. M., Agca, A., Ozgurhan, E. B., Karakucuk, Y., Yazici, A. T., & Demirok, A. (2013). Is spectral-domain optical coherence tomography essential for flexible treatment regimens with ranibizumab for neovascular age-related macular degeneration?. Journal of ophthalmology, 2013786107. https://doi.org/10.1155/2013/786107
Ozkaya, Abdullah, et al. "Is spectral-domain optical coherence tomography essential for flexible treatment regimens with ranibizumab for neovascular age-related macular degeneration?." Journal of ophthalmology vol. 2013 (2013): 786107. doi: https://doi.org/10.1155/2013/786107
Ozkaya A, Alkin Z, Ozkaya HM, Agca A, Ozgurhan EB, Karakucuk Y, Yazici AT, Demirok A. Is spectral-domain optical coherence tomography essential for flexible treatment regimens with ranibizumab for neovascular age-related macular degeneration?. J Ophthalmol. 2013;2013:786107. doi: 10.1155/2013/786107. Epub 2013 Nov 11. PMID: 24324880; PMCID: PMC3844228.
Copy
Download .nbib